Navigation Links
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
Date:11/2/2009

FREMONT, Calif., Nov. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel RNA interference (RNAi)-based therapeutics, today announced that James D. Thompson, Ph.D., Vice President, Pharmaceutical Development, will present a case history of QPI-1002, the first systemically administered synthetic siRNA, at the Joint Symposium of the 5th Annual Meeting of Oligonucleotide Therapeutics Society and the 19th Antisense Symposium in Fukuoka, Japan, November 3-6, 2009. The company also announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, will participate in the RNAi for Developing Targeted Therapeutics track at this year's CHI Discovery on Target Conference in Boston, November 2-4, 2009.

Dr. Thompson's presentation will be part of a session titled, "Clinical Studies and Therapeutic Development," which will be held on Thursday, November 5. The case study on QPI-1002 will detail Quark's progress in its independent development of the first systemic administration of a synthetic siRNA in humans, results from Quark's IND-enabling efficacy and toxicology studies and the largest cGMP manufacture of synthetic siRNA of its time. Dr. Feinstein's presentation, titled "Use of siRNA for Amelioration of Aseptic Lung Inflammatory Conditions," will take place on Wednesday, November 4 and will present Quark's preclinical studies for aseptic lung inflammation.

Daniel Zurr, Ph.D., President and Chief Executive Officer of Quark, said, "Drs. Thompson and Feinstein's presentations demonstrate Quark's leadership and continued innovation in the discovery and development of siRNA therapeutics. Quark's strength in preclinical discovery has promoted development of a robust pipeline that provides our company with growth opportunities within a broad range of therapeutic areas. We are nicely positioned to progress our clinical stage drug candidates, including the first systemically administered siRNA, as well as additional pre-clinical stage compounds, through important value-enhancing milestones in 2010. We look forward to presenting these case studies reflecting the success of our proprietary programs."

QPI-1002 targets p53, a stress-response gene that plays a pivotal role in the apoptotic pathway. Temporary inhibition of p53 at the time of injury delays cell death, allowing natural repair mechanisms to restore normal DNA and cellular integrity. QPI-1002 is currently being evaluated in a Phase I/IIa clinical study for the prevention of acute kidney injury (AKI) and in Part A of a Phase I/II clinical study for the prophylaxis of delayed graft function (DGF) following renal transplantation. Both studies are scheduled to be completed this year.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to target tissues and organs including the eye, ear, lung, spinal cord and brain.

Quark's clinical pipeline includes PF-4523655 (RTP801i-14), currently in Phase II clinical trials for Diabetic Macular Edema (DME) and Age-related Macular Degeneration (AMD). PF-4523655 is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam Pharmaceuticals.

Furthermore, QPI-1007, a proprietary siRNA drug candidate that utilizes a proprietary structure developed by Quark, is being evaluated in advanced IND-enabling preclinical studies as a neuroprotective agent for eye diseases. In addition, Quark has a broad pipeline of siRNA drug candidates and potential drug candidates that have arisen from Quark's research activities. The Company is committed to development of novel siRNA structures and expects to utilize these structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.

    Quark Pharmaceuticals, Inc.         The Ruth Group (investors / media)
    Juliana Friedman                    Sara Ephraim / Janine McCargo
    +972 89 30 5111                     (646) 536-7004 / 7033
    jfriedman@quarkpharma.com           sephraim@theruthgroup.com
                                        jmccargo@theruthgroup.com

SOURCE Quark Pharmaceuticals, Inc.


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
2. Quark Pharmaceuticals Presents at Asia TIDES Conference
3. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016   GS1 US will ... guide them through GS1 Standards implementation to address the ... Unique Device Identification (UDI) rule. Scott ... Beth Gibson , senior director industry development, medical devices, ... director, GS1 US --> Scott ...
(Date:2/8/2016)... Feb. 8, 2016 Nueterra, the ... specialized in the development of equity partnerships ... it has divided its interests between two ... Capital will continue the founding company,s private ... operate a national system of integrated provider ...
(Date:2/8/2016)... Pa. , Feb. 8, 2016   ... November Research Group (NRG),s pharmacovigilance technology services ... system-related consulting services and an Oracle Argus Specialized ... services to Life Sciences companies. ... and expands HighPoint,s life sciences capabilities and provides ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... ... states in the U.S. require dental technicians to be certified or obtain continuing ... industry, NADL created the “What’s In Your Mouth?” campaign to inform dentists and ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women's Excellence staff, in all four locations, wore ... Wear Red Day is the first Friday each February and a day to bring ... in 3 deaths among women each year – more than all cancers combined. Go ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
(Date:2/6/2016)... ... ... US Sports Camps is proud to sponsor the Bay Area Disc Association's ... leaders, ultimate organizations, and coaches from around the US. The theme for this year’s ... of Youth and Education, describes this year YUCC as “an important conversation we must ...
(Date:2/6/2016)... , ... February 06, 2016 , ... Shark Finds ... announce the launch of a new DRTV campaign with Belly Bands. , Having a ... everything from sprays to puppy pads and find nothing works, get Belly Bands, ...
Breaking Medicine News(10 mins):